Progression, Disease
11
3
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease
Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy
SLNB After Neoadjuvant Treatment in Node Positive Patients
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action
The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder Cancer
Neuromelanin MRI: A Progression Marker in Early PD
Energy for Lymphocytes
Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy